Review
Efficacy of polyphenolic ingredients of Chinese herbs in treating dyslipidemia of metabolic syndromes

https://doi.org/10.1016/S2095-4964(14)60023-6Get rights and content

Abstract

There is an increasing interest and popularity of Chinese herbal medicine worldwide, which is accompanied by increasing concerns about its effectiveness and potential toxicity. Several ingredients, such as polyphenolic compounds berberine, flavonoids, and curcumin, have been studied extensively by using various animal models. Effectiveness of treatment and amelioration of metabolic syndromes, including insulin resistance and dyslipidemia, has been demonstrated. This review summarizes the major checkpoints and contributing factors in regulation of exogenous and endogenous lipid metabolism, with particular emphasis centered on triglyceride-rich and cholesterol-rich lipoproteins. Available experimental evidence demonstrating the lipid-lowering effect of berberine, flavonoids and curcumin in cell culture and animal models is compiled, and the strengths and shortcomings of experimental designs in these studies are discussed.

References (89)

  • MG Myers et al.

    Challenges and opportunities of defining clinical leptin resistance

    Cell Metab

    (2012)
  • B Löllmann et al.

    Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues

    Biochem Biophys Res Commun

    (1997)
  • MS Brown et al.

    Selective versus total insulin resistance: a pathogenic paradox

    Cell Metab

    (2008)
  • TL Phung et al.

    Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum

    J Biol Chem

    (1997)
  • Y Hu et al.

    Berberine inhibits adipogenesis in high-fat diet-induced obesity mice

    Fitoterapia

    (2010)
  • J Yin et al.

    Efficacy of berberine in patients with type 2 diabetes mellitus

    Metabolism

    (2008)
  • H Zhang et al.

    Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression

    Metabolism

    (2010)
  • J Zhou et al.

    Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes

    Eur J Pharmacol

    (2010)
  • H Li et al.

    Hepatocyte nuclear factor 1α plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

    J Biol Chem

    (2009)
  • GS Li et al.

    Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver X receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters

    Biol Pharm Bull

    (2011)
  • C Chen et al.

    Berberine inhibits PTP1B activity and mimics insulin action

    Biochem Biophys Res Commun

    (2010)
  • Z Cheng et al.

    Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK

    Biochim Biophys Acta

    (2006)
  • X Chang et al.

    Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats

    J Lipid Res

    (2010)
  • Y Zhou et al.

    Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells

    Fitoterapia

    (2014)
  • SI Koo et al.

    Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect

    J Nutr Biochem

    (2007)
  • EM Jang et al.

    Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters

    Metabolism

    (2008)
  • MJ Graham et al.

    Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

    Circ Res

    (2013)
  • MM Hussain et al.

    Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism

    Curr Opin Lipidol

    (2008)
  • Aegerion Pharmaceuticals, Inc.

    FDA approves Aegerion Pharmaceuticals’ JUXTAPID™ (lomitapide) Capsules for homozygous familial hypercholesterolemia (HoFH). (2012-12-24) [2013-6-15]

  • M Sundaram et al.

    Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion

    Arterioscler Thromb Vasc Biol

    (2012)
  • Z Yao et al.

    Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production

    Curr Opin Lipidol

    (2012)
  • FF Samaha et al.

    Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia

    Nat Clin Pract Cardiovasc Med

    (2008)
  • JL Goldstein et al.

    The LDL receptor

    Arterioscler Thromb Vasc Biol

    (2009)
  • D Steinberg et al.

    Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

    Proc Natl Acad Sci U S A

    (2009)
  • JM Timmins et al.

    Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I

    J Clin Invest

    (2005)
  • X Wang et al.

    Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo.

    J Clin Invest

    (2007)
  • E Orso et al.

    Transport of lipids from Golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice

    Nat Genet

    (2000)
  • R Knox

    Merck: niacin drug mix fails to prevent heart attacks, strokes. (2012-12-20) [2013-6-20]

  • EL Klett et al.

    Genetic defenses against noncholesterol sterols

    Curr Opin Lipidol

    (2003)
  • SW Altmann et al.

    Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption

    Science

    (2004)
  • M Garcia-Calvo et al.

    The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1)

    Proc Natl Acad Sci U S A

    (2005)
  • L Grigore et al.

    Combination therapy in cholesterol reduction: focus on ezetimibe and statins

    Vasc Health Risk Manag

    (2008)
  • JR Burnett et al.

    MTP inhibition as a treatment for dyslipidemias: time to deliver or empty promises?

    Expert Opin Ther Targets

    (2007)
  • B Jones et al.

    Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders

    Nat Genet

    (2003)
  • Cited by (0)

    View full text